Clinical Trials | A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRa-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The University of Virginia seeks women age 18 years and older to participate in a clinical trial. You may be eligible for this study if you have newly diagnosed (untreated) advanced stage folate receptor alpha (FRa) expressing positive ovarian, fallopian tube, or primary peritoneal cancer. This study will test two drugs called Mirvetuximab Soravtansine (MIRV) and Carboplatin to treat your cancer. These study drugs will be administered intravenously (IV) on the first day of each cycle, every 21 days for up to 6-9 cycles. Mirvetuximab Soravtansine (MIRV) is not approved by the U.S. Food and Drug Administration (FDA) to treat Ovarian Cancer. Surgery will be planned after the investigational neoadjuvant treatment at the discretion of your treatment provider. This study will include: blood draws, tumor imaging assessments, and eye exams. If you choose to participate in this study, you may be participating in study activities for up to 3 years. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.